Aspirin for the primary prevention of cardiovascular events: recommendation and rationale
about
sameAs
Aspirin for primary prevention of coronary heart diseasePrevalence of antiplatelet therapy in patients with diabetes.Underutilization of aspirin persists in US ambulatory care for the secondary and primary prevention of cardiovascular disease.Heart to Heart: a computerized decision aid for assessment of coronary heart disease risk and the impact of risk-reduction interventions for primary preventionThe cost-effectiveness of aspirin versus cyclooxygenase-2-selective inhibitors for colorectal carcinoma chemoprevention in healthy individualsMinimizing complications from nonsteroidal antiinflammatory drugs: cost-effectiveness of competing strategies in varying risk groupsPreventable stroke and stroke preventionAntiplatelet therapy and the vascular treePrimary prevention of coronary heart disease with aspirinUnderuse of antiplatelets and inappropriate useSex-related differences in response to aspirin in cardiovascular disease: an untested hypothesisA multi-country economic evaluation of low-dose aspirin in the primary prevention of cardiovascular diseasePrimary care physician perceptions of non-steroidal anti-inflammatory drug and aspirin-associated toxicity: results of a national surveyPerceived discrimination and use of preventive health servicesThe cost-effectiveness of drug treatments for primary prevention of cardiovascular disease: a modelling studyWhich patients should receive aspirin for primary prevention of cardiovascular disease? An economic evaluationReview article: gastrointestinal bleeding with low-dose aspirin - what's the risk?Current developments in anti-platelet therapyDose of aspirin in the treatment and prevention of cardiovascular disease: current and future directionsAnalysis of aspirin-associated risks in healthy individualsThe rise and decline of nonsteroidal antiinflammatory drug-associated gastropathy in rheumatoid arthritisAspirin, NSAIDs, and COX-2 inhibitors in cardiovascular disease: possible interactions and implications for treatment of rheumatoid arthritisFrequent monthly use of selected non-prescription and prescription non-narcotic analgesics among U.S. adultsGender differences in aspirin use among adults with coronary heart disease in the United StatesA large cohort study of long-term daily use of adult-strength aspirin and cancer incidenceDoes the routine use of global coronary heart disease risk scores translate into clinical benefits or harms? A systematic review of the literature.Psoriasis: an opportunity to identify cardiovascular risk.Whole blood viscosity assessment issues III: Association with international normalized ratio and thrombocytopeniaNeighborhood socioeconomic status, Medicaid coverage and medical management of myocardial infarction: atherosclerosis risk in communities (ARIC) community surveillance.Aspirin for primary cardiovascular prevention: when is it worth the risks?Cost-effectiveness of aspirin use among persons with newly diagnosed type 2 diabetes.Socioeconomic and ethnic disparities in cardiovascular risk in the United States, 2001-2006.Decreased risk of squamous cell carcinoma of the head and neck in users of nonsteroidal anti-inflammatory drugsAssociation between Psoriasis and Cardiovascular Risk Factors in Korean Patients.Comparison of the racial/ethnic prevalence of regular aspirin use for the primary prevention of coronary heart disease from the multi-ethnic study of atherosclerosis.Aspirin overutilization for the primary prevention of cardiovascular disease.Atherosclerotic risk factor reduction in peripheral arterial diseasea: results of a national physician surveyClinical preventive services for patients at risk for cardiovascular disease, National Ambulatory Medical Care Survey, 2005-2006.Use of aspirin for primary and secondary cardiovascular disease prevention in the United States, 2011-2012.Do clinicians recommend aspirin to patients for primary prevention of cardiovascular disease?
P2860
Q24247631-00898F61-4A43-4085-94A0-E7D024CB4109Q24813940-B83D6DF7-D20E-4941-B483-38508A000F66Q24816911-0AB74E5F-45A7-4C77-9D1D-D921AB289A11Q28167662-8BC950AC-D208-483A-8D59-78CB7377167FQ28169129-A174D672-EE12-4ABE-AC8C-1CD06B7CD101Q28173947-77A74A6C-C1BD-429E-9633-CCB95D7FD3FFQ28187602-3CE7693D-5EE5-4E7D-B5BB-57E42F33B3B2Q28192565-598B91EC-CF4D-4F4E-9E10-96A41F899524Q28192984-563A79C4-6457-4D4C-A780-5BC46DE740C7Q28193683-B7D4039D-8DA1-426C-B740-CCD132CF3C59Q28194340-D74171AF-A948-4302-ADAE-AD21CC932A40Q28194877-A7FE477B-8626-46C7-BEF9-93D41ACED21AQ28195079-7E62FDF5-A00B-414B-8ABA-A82CFBEB2ABBQ28198594-9707A0D1-2583-48B7-A041-99C26D48A4FCQ28199830-4FC35F89-FA16-4A82-B5EA-254251AC4F55Q28200339-D5B0AF5F-9F02-4639-BA92-2199EEC15861Q28200403-4DDD7671-3D5E-4F5C-A94A-69A66EDB29BDQ28200685-C794688E-EBF2-4C2D-BAFD-599151E4E6C2Q28200895-C721884E-C791-4FAA-BFB0-8C944E34F141Q28211608-BF730B3B-42F7-48CA-9908-94A8FE6B135BQ28211833-C059C5F0-59FE-4171-AB54-DCBF536AB902Q28212591-217014F3-A4AE-434E-A9B7-C69F674B885DQ28213637-665F3296-AC99-4E20-9610-7923FA3F4998Q28220649-F8937D88-A021-4721-976A-7DA49EAF9416Q28222395-24875F62-ED9E-41D1-9A2A-178FB4CEE628Q33325717-D0EC87D2-4962-42B7-B153-E3397E4CC3C2Q33385270-8B297D61-4B52-45B9-BAC0-E9378934025FQ33401066-F2E1D34C-9D23-49AD-BAEC-8AD7DE1E6806Q33724790-411D4B59-FE5F-4726-B8A1-8C3AA4F5082AQ33774734-837C9952-AD3C-4D6B-8975-44D2755B73D7Q33873025-184D9278-AC93-4B43-BCC8-CE423469DE1DQ33984096-7EC410EE-036F-457C-8358-F934E4B55E68Q33984604-EA5294E1-4898-4707-9B15-1A7685913A1CQ34050825-339D4432-93ED-49AD-BD3C-E0274CA0ACA1Q34491092-D56D9CCD-019E-4822-84EF-083E1C2B554AQ34657167-7721BA66-6A50-435C-B64F-11222387E532Q34743538-E1EAD564-08F7-42BB-BC99-F24D372F4D9FQ34776079-2A74B68C-FFD6-48EB-AD15-F824B1F87946Q35026319-8392E8E7-9A9F-43EF-9885-1B45AB959C6DQ35040366-359586B7-E254-4AA3-A152-9515B23E92E1
P2860
Aspirin for the primary prevention of cardiovascular events: recommendation and rationale
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Aspirin for the primary prevention of cardiovascular events: recommendation and rationale
@ast
Aspirin for the primary prevention of cardiovascular events: recommendation and rationale
@en
Aspirin for the primary prevention of cardiovascular events: recommendation and rationale
@nl
type
label
Aspirin for the primary prevention of cardiovascular events: recommendation and rationale
@ast
Aspirin for the primary prevention of cardiovascular events: recommendation and rationale
@en
Aspirin for the primary prevention of cardiovascular events: recommendation and rationale
@nl
prefLabel
Aspirin for the primary prevention of cardiovascular events: recommendation and rationale
@ast
Aspirin for the primary prevention of cardiovascular events: recommendation and rationale
@en
Aspirin for the primary prevention of cardiovascular events: recommendation and rationale
@nl
P1476
Aspirin for the primary prevention of cardiovascular events: recommendation and rationale
@en
P304
P356
10.7326/0003-4819-136-2-200201150-00015
P407
P577
2002-01-15T00:00:00Z